RSV vaccine safety and immune response study for older adults
Treatments studied
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You are generally in good health, or your chronic conditions (like diabetes or high blood pressure) have been stable for the past 3 months.
- You have not received any RSV vaccine or RSV antibody before, and you have not had an RSV infection in the last 6 months.
- You are not taking long-term immunosuppressive drugs (like high-dose steroids for 14 days or more).
- You have not received other vaccines within 30 days (live) or 14 days (non-live) before the trial, and you can avoid them during the trial.
- You do not have severe allergies to vaccine components, a weakened immune system, or certain serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
Hear when a new Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.